# Vivek Lal

> Dr. C. Vivek Lal is a physician-scientist turned founder who runs resbiotic, a Birmingham-based wellness company building clinically tested probiotic and prebiotic supplements on a 'Gut-X Axis' platform. A double board-certified neonatologist who directs the Pulmonary Microbiome Lab at the University of Alabama at Birmingham, Lal turned more than 100 peer-reviewed papers and NIH-funded lab work into a string of companies, including the drug-development firm Alveolus Bio and the pediatric chain Urgent Care for Children. In September 2025, resbiotic closed an $8 million Series A, bringing its total funding to $14.5 million.

- **Role:** Founder & CEO at resbiotic
- **Organizations:** resbiotic Nutrition, Inc., Alveolus Bio, Inc., Urgent Care for Children, University of Alabama at Birmingham (UAB), Marnix Heersink Institute of Biomedical Innovation, Biostack Ventures
- **From:** Andaman Islands, India
- **Nationality:** Indian-American
- **Education:** Residency, clinical fellowship in neonatal & perinatal medicine, research fellowship in pulmonary & vascular biology, UT Southwestern Medical Center, Dallas, Executive program in drug & device development, Massachusetts Institute of Technology (MIT)
- **Known for:** Author of 100+ peer-reviewed research manuscripts and abstracts, Holder of multiple patents in microbiome science, Secured NIH-NHLBI and American Heart Association research funding

## Career timeline

- **earlier** — Practices as an ICU/neonatology physician and builds the Pulmonary Microbiome Lab at UAB, funded by NIH-NHLBI and the American Heart Association
- **2019** — Co-founds Urgent Care for Children, a Southeast US pediatric urgent care chain, with his wife
- **2021** — Founds Alveolus Bio, a platform biotech for FDA-track pulmonary drug development
- **2022** — Launches resbiotic Nutrition to make clinically tested microbiome supplements
- **2023** — Recognized at UAB Harbert Institute Innovation Awards
- **2025** — resbiotic closes an $8M Series A; total funding reaches $14.5M

## Achievements

- Author of 100+ peer-reviewed research manuscripts and abstracts
- Holder of multiple patents in microbiome science
- Secured NIH-NHLBI and American Heart Association research funding
- Founder of resbiotic, maker of the first clinically tested probiotic targeting the gut-lung axis
- Founder & Executive Chairman of Alveolus Bio
- Co-founder of Urgent Care for Children
- Director of Clinical Innovation at UAB's Marnix Heersink Institute of Biomedical Innovation
- Raised $14.5M total for resbiotic including an $8M Series A (2025)

## Latest updates

- **2025-09** — resbiotic announced an $8M Series A round, bringing total funding to $14.5M, backed by Sororibus Capital and Biostack Ventures, to expand its product portfolio and retail/ecommerce distribution.

## Links

- Website: https://resbiotic.com
- LinkedIn: https://www.linkedin.com/in/c-vivek-lal-md-faap-20183913/
- Twitter/X: https://twitter.com/resbiotic
- Facebook: https://facebook.com/resbiotic

---

Profile page: https://yespress.io/vivek-lal
Published by YesPress — https://yespress.io
Last updated: 2026-06-11